Skip to main content
. 2020 Mar 7;10(3):416. doi: 10.3390/biom10030416

Figure 4.

Figure 4

ADAMTS-5 blockade does not decrease versican processing. Representative images of versikine immunoreactivity (red) on EDL cross-sections from mdx mice treated with IgG control (A; n = 3) or ADAMTS-5 mAb (B; n = 3); nuclei (blue). Versikine protein levels in EDL and soleus muscles (C and D; n = 5 per muscle and treatment group) and (E) V0 and V1 Versican gene expression in dystrophic EDL muscles following ADAMTS-5 blockade. *P = 0.01, independent t-test. N = 5 mice for versikine immunoblotting and n = 13 mice for V0 and V1 versican gene expression. Scale bar = 100 µm.